Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101599 | NOVARTIS | Pharmaceutical composition containing anti-hypertensive agents |
May, 2023
(4 months ago) | |
US8475839 | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
May, 2023
(4 months ago) | |
US8475839 (Pediatric) | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Nov, 2023
(a month from now) |
Exforge Hct is owned by Novartis.
Exforge Hct contains Amlodipine Besylate; Hydrochlorothiazide; Valsartan.
Exforge Hct has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Exforge Hct are:
Exforge Hct was authorised for market use on 30 April, 2009.
Exforge Hct is available in tablet;oral dosage forms.
The generics of Exforge Hct are possible to be released after 16 November, 2023.
Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient
Market Authorisation Date: 30 April, 2009
Treatment: NA
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic